Background: Most patients with cholangiocarcinoma (CCA) have unresectable disease. Endoscopic bile duct drainage is one of the major objectives of palliation of obstructive jaundice. Methods/Results: Stent implantation using endoscopic retrograde cholangiography is considered to be the standard technique. Unilateral versus bilateral stenting is associated with different advantages and disadvantages; however, a standard approach is still not defined. As there are various kinds of stents, there is an ongoing discussion on which stent to use in which situation. Palliation of obstructive jaundice can be augmented through the use of photodynamic therapy (PDT). Studies have shown a prolonged survival for the combinations of PDT and different stent applications as well as combinations of PDT and additional systemic chemotherapy. Conclusion: More well-designed studies are needed to better evaluate and standardize endoscopic treatment of unresectable CCA.

Keywords:
Cholangiocarcinoma, Endoscopic therapy, Photodynamic therapy
1.
Hochwald SN, Burke EC, Jarnagin WR, Fong Y, Blumgart LH: Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999;134:261-266.
2.
Lai EC, Lau SH, Lau WY: The current status of preoperative biliary drainage for patients who receive pancreaticoduodenectomy for periampullary carcinoma: a comprehensive review. Surgeon 2014;12:290-296.
3.
Iacono C, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A: Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg 2013;257:191-204.
4.
Andersen JR, Sorensen SM, Kruse A, Rokkjaer M, Matzen P: Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989;30:1132-1135.
5.
Tibble JA, Cairns SR: Role of endoscopic endoprostheses in proximal malignant biliary obstruction. J Hepatobiliary Pancreat Surg 2001;8:118-123.
6.
Larghi A, Tringali A, Lecca PG, Giordano M, Costamagna G: Management of hilar biliary strictures. Am J Gastroenterol 2008;103:458-473.
7.
Yasuda I, Mukai T, Moriwaki H: Unilateral versus bilateral endoscopic biliary stenting for malignant hilar biliary strictures. Dig Endosc 2013;25(suppl 2):81-85.
8.
Chang WH, Kortan P, Haber GB: Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998;47:354-362.
9.
Naitoh I, Ohara H, Nakazawa T, et al: Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. J Gastroenterol Hepatol 2009;24:552-557.
10.
De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C: Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001;53:547-553.
11.
Iwano H, Ryozawa S, Ishigaki N, et al: Unilateral versus bilateral drainage using self-expandable metallic stent for unresectable hilar biliary obstruction. Dig Endosc 2011;23:43-48.
12.
Levy MJ, Baron TH, Gostout CJ, Petersen BT, Farnell MB: Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: an evidence-based approach. Clin Gastroenterol Hepatol 2004;2:273-285.
13.
Baron TH: Palliation of malignant obstructive jaundice. Gastroenterol Clin North Am 2006;35:101-112.
14.
Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K: Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488-1492.
15.
Mukai T, Yasuda I, Nakashima M, et al: Metallic stents are more efficacious than plastic stents in unresectable malignant hilar biliary strictures: a randomized controlled trial. J Hepatobiliary Pancreat Sci 2013;20:214-222.
16.
Kaassis M, Boyer J, Dumas R, et al: Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 2003;57:178-182.
17.
Yeoh KG, Zimmerman MJ, Cunningham JT, Cotton PB: Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc 1999;49:466-471.
18.
Leggett CL, Gorospe EC, Murad MH, Montori VM, Baron TH, Wang KK: Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn Ther 2012;9:189-195.
19.
Lu Y, Liu L, Wu JC, Bie LK, Gong B: Efficacy and safety of photodynamic therapy for unresectable cholangiocarcinoma: a meta-analysis. Clin Res Hepatol Gastroenterol 2015;39:718-724.
20.
Yang J, Shen H, Jin H, Lou Q, Zhang X: Treatment of unresectable extrahepatic cholangiocarcinoma using hematoporphyrin photodynamic therapy: a prospective study. Photodiagnosis Photodyn Ther 2016;DOI: 10.1016/j.pdpdt.2016.10.001.
21.
Park DH, Lee SS, Park SE, et al: Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. Eur J Cancer 2014;50:1259-1268.
22.
Wentrup R, Winkelmann N, Mitroshkin A, et al: Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma. Gut Liver 2016;10:470-475.
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.